LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Home・Aandelen Lijst・Lisata Therapeutics

L
Lisata Therapeutics

Gesloten

2.01 -3.83

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

2.01

Belangrijke statistieken
By Trading Economics
Werknemers	26

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-4.7M 15M
Vorige openingsprijs	5.84
Vorige sluitingsprijs	2.01

Lisata Therapeutics Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 dec 2025, 21:41 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 dec 2025, 14:57 UTC

Acquisities, Fusies, Overnames

Accenture to Acquire Cabel Industry from Fibonacci Group

25 dec 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 dec 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 dec 2025, 00:20 UTC

Acquisities, Fusies, Overnames

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 dec 2025, 22:22 UTC

Acquisities, Fusies, Overnames

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dec 2025, 19:35 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 dec 2025, 19:35 UTC

Marktinformatie

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dec 2025, 19:06 UTC

Marktinformatie

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 dec 2025, 19:03 UTC

Marktinformatie

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 dec 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

24 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

24 dec 2025, 17:08 UTC

Acquisities, Fusies, Overnames

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec 2025, 16:53 UTC

Acquisities, Fusies, Overnames

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 dec 2025, 16:31 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 dec 2025, 16:28 UTC

Acquisities, Fusies, Overnames

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 dec 2025, 16:17 UTC

Marktinformatie

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 dec 2025, 15:33 UTC

Acquisities, Fusies, Overnames

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 dec 2025, 15:30 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec 2025, 15:19 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec 2025, 14:49 UTC

Acquisities, Fusies, Overnames

Mexico's Ollamani Sells Stake in Azteca Stadium

24 dec 2025, 14:19 UTC

Marktinformatie

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 dec 2025, 14:08 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec 2025, 14:06 UTC

Marktinformatie

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 dec 2025, 13:24 UTC

Marktinformatie

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 dec 2025, 12:59 UTC

Acquisities, Fusies, Overnames

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec 2025, 12:51 UTC

Acquisities, Fusies, Overnames

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

Peer Vergelijking

Prijswijziging

Lisata Therapeutics Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Lisata Therapeutics - Dist in de afgelopen 3 maanden.

Financieel

Over Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.